Market Newsdesk

VANCOUVER, British Columbia, Dec. 03, 2020 (GLOBE NEWSWIRE) — Clean Power Capital Corp. (CSE: MOVE)(FWB: 2K6)(OTC: MOTNF) (“Clean Power” or the “Company” or “MOVE“). The Company is pleased to announce that the Board of the Company has formed a strategic committee (the “Strategic Committee”) to review and develop a strategy to enhance its investor profile by launching a new capital markets strategy focused on the United States. As part of the strategy, the Strategic Committee will consider an application to list its common shares on the NASDAQ Capital Market (“NASDAQ”).

The acceptance of the application to list the Company’s common shares on NASDAQ will be subject to a number of regulatory and listing requirements, including without limitation: retaining the required number of market makers for the Company’s common shares; engaging a sponsor for the Company’s common shares; the filing of the applicable registration statement with the U.S. Securities and Exchange Commission to become a reporting company under the U.S. Securities Act; and the review of the Company and acceptance for listing by NASDAQ. The Company will also seek a financial advisor to assess the viability of a potential up-listing to NASDAQ. There can be no assurance that NASDAQ acceptance will be granted should the Company submit its listing application.

Management of MOVE believes up-listing to NASDAQ will:

• provide additional opportunities to attract institutional and retail investors, allowing the Company to broaden its investor base in the United States and internationally;
• increase the visibility of the Company, its growth strategy, accomplishments and results to date;
• increase liquidity of the Company’s common shares; and
• raise the Company’s overall profile and ultimately enhance shareholder value.

Joel Dumaresq, CEO of the MOVE stated, “We continue to see strong interest from investors both in the U.S. and internationally. An up-listing to the NASDAQ has been on our radar as one of the many strategies to execute as part of our capital markets strategy and in accordance with the Company’s Investment Policy with the paramount goal of the Company to generate maximum returns from its investments. Given that a NASDAQ listing is a natural next step for the Company.”

The listing of the Company’s common shares on the NASDAQ remains subject to the approval of the NASDAQ and the satisfaction of all applicable listing and regulatory requirements. The Company will continue to maintain the listing of its common shares on the Canadian Securities Exchange under the symbol “MOVE”. The Company will provide updates on its progress as it moves toward this goal.

There is currently no timeline for completion of the review of our capital markets strategy, and there is no assurance that these efforts will be successful or that the review process will result in the listing of the Company’s common shares on NASDAQ.

About PowerTap

The Company completed an investment in PowerTap on October 27, 2020 (see the Company’s news release on October 28, 2020). PowerTap is leading the charge to build out cost-effective hydrogen fueling infrastructure through its environmentally friendly intellectual property, product design for the modularized and lowest tier production cost of hydrogen, and launch plan.   PowerTap technology-based hydrogen fueling stations are located in private enterprises and public stations (near LAX airport) in California, Texas, Massachusetts, and Maryland. Additional information about PowerTap may be found at its website at http://www.powertapfuels.com

ABOUT
CLEAN POWER
CAPITAL CORP.

Clean Power is an investment company, that specializes in investing into private and public companies opportunistically that may be engaged in a variety of industries, with a current focus in the health and renewable energy industries. In particular, the investment mandate is focused on high return investment opportunities, the ability to achieve a reasonable rate of capital appreciation and to seek liquidity in our investments. A copy of Clean Power’s amended and restated investment policy may be found under the Company’s profile at www.sedar.com.

ON BEHALF OF THE
CLEAN POWER
CAPITAL CORP.
BOARD OF DIRECTORS

“Joel Dumaresq”

Joel Dumaresq, CEO
+1 (604) 687-2038
i[email protected]

Learn more about Clean Power by visiting our website at: https://cleanpower.capital/

Notice Regarding Forward Looking Information:

This press release contains “forward-looking information” and “forward-looking statements” (together, “forward-looking statements”) within the meaning of applicable Canadian and United States securities laws. Forward-looking statements are often, but not always, identified by the use of words such as “seek”, “anticipate”, “believe”, “plan”, “estimate”, “expect”, “likely” and “intend” and statements that an event or result “may”, “will”, “should”, “could” or “might” occur or be achieved and other similar expressions. Forward-looking information in this press release includes statements relating to the Company’s consideration of applying to list its common shares on NASDAQ, the Company’s ability to increase its liquidity and capital markets exposure if the NASDAQ listing application is submitted and is successful, the Company receiving all required approvals in respect of a potential NASDAQ listing application and the commencement of trading of the Company’s Common Shares on the NASDAQ should a listing application be submitted and accepted, the planned registration of the Company’s common shares with the U.S. Securities and Exchange Commission (the “SEC”), the timing of the SEC’s review of the proposed application and any delays, including but not limited to delays related to COVID-19, and the Company’s strategic plans.

Although the Company believes that the material factors, expectations and assumptions expressed in such forward-looking statements are reasonable based on information available to it on the date such statements were made, no assurances can be given as to future results, levels of activity and achievements and such statements are not guarantees of future performance.

The forward-looking information contained in this release is expressly qualified by the foregoing cautionary statements and is made as of the date of this release. Except as may be required by applicable securities laws, the Company does not undertake any obligation to publicly update or revise any forward-looking information to reflect events or circumstances after the date of this release or to reflect the occurrence of unanticipated events, whether as a result of new information, future events or results, or otherwise.

THE CSE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE.

SAN DIEGO, Dec. 02, 2020 (GLOBE NEWSWIRE) — Progenity, Inc. (NASDAQ: PROG) today announced the pricing of its offering of $75.0 million aggregate principal amount of 7.25% convertible senior notes due 2025 (the “notes”) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The issuance and sale of the notes are scheduled to settle on December 7, 2020, subject to customary closing conditions. Progenity also granted the initial purchaser of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date notes are first issued, up to an additional $15.0 million principal amount of notes.

The notes will be senior, unsecured obligations of Progenity and will accrue interest at a rate of 7.25% per annum, payable semi-annually in arrears on June 1 and December 1 of each year, beginning on June 1, 2021. The notes will mature on December 1, 2025, unless earlier repurchased, redeemed or converted. At any time from, and including, the date that is 30 calendar days after the initial closing date of this offering and before the close of business on the second scheduled trading day immediately before the maturity date, noteholders may convert their notes at their option into shares of Progenity’s common stock, together, if applicable, with cash in lieu of any fractional share, at the then-applicable conversion rate. In addition, noteholders that convert their notes before December 1, 2022 will, in certain circumstances, be entitled to an additional cash payment representing the present value of any remaining interest payments on the notes through December 1, 2022. The initial conversion rate is 278.0094 shares of common stock per $1,000 principal amount of notes, which represents an initial conversion price of approximately $3.60 per share of common stock. The conversion rate and conversion price will be subject to adjustment upon the occurrence of certain events.

The notes will be redeemable, in whole and not in part, for cash at Progenity’s option at any time on or after December 1, 2023, but only if the last reported sale price per share of Progenity’s common stock exceeds 130% of the conversion price for a specified period of time. The redemption price will be equal to the principal amount of the notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date.

If a “fundamental change” (as defined in the indenture for the notes) occurs, then noteholders may require Progenity to repurchase their notes for cash. The repurchase price will be equal to the principal amount of the notes to be repurchased, plus accrued and unpaid interest, if any, to, but excluding, the applicable repurchase date.

Progenity estimates that the net proceeds from the offering will be approximately $70.8 million (or approximately $85.0 million if the initial purchaser fully exercise its option to purchase additional notes), after deducting the initial purchaser’s discounts and commissions and estimated offering expenses. Progenity intends to use the net proceeds from the offering, together with the net proceeds from the underwritten public offering of common stock referred to below, to support its operations, to invest in its molecular testing research and development program, to invest in research and development with respect to its precision medicine platform, and for working capital and general corporate purposes.

Certain entities affiliated with Athyrium Capital Management, LP (“Athyrium”), one of Progenity’s affiliates, have agreed to acquire up to $103.5 million in aggregate principal amount of notes, consisting of $25.0 million principal amount of notes to be purchased for cash in the offering and, pursuant to a separate exchange agreement, an additional $78.5 million principal amount of notes to be issued in exchange for the discharge of amounts outstanding under Progenity’s credit and security agreement with a fund managed by Athyrium.

In a separate press release, Progenity also announced today the pricing of its previously announced underwritten public offering of 7,645,259 shares of common stock, at a public offering price of $3.27 per share. The issuance and sale of the common stock are scheduled to settle on December 7, 2020, subject to customary closing conditions. Progenity also granted the underwriters of the common stock offering a 30-day option to purchase up to an additional 1,146,788 shares of common stock. The completion of the offering of the notes is not contingent on the completion of the offering of common stock, and the completion of the offering of common stock is not contingent on the completion of offering of the notes. This press release does not constitute an offer to sell, or the solicitation of an offer to buy, any common stock in the public offering.

The offer and sale of the notes and the shares of common stock issuable upon conversion of the notes have not been, and will not be, registered under the Securities Act or any other securities laws, and the notes and such shares cannot be offered or sold except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and any other applicable securities laws. This press release does not constitute an offer to sell, or the solicitation of an offer to buy, the notes or the shares of common stock issuable upon conversion of the notes, nor will there be any sale of the notes or such shares, in any state or other jurisdiction in which such offer, sale or solicitation would be unlawful.

About
Progenity

Progenity, Inc. is a biotechnology company with an established track record of success in developing and commercializing molecular testing products, as well as innovating in the field of precision medicine. Progenity provides in vitro molecular tests designed to improve lives by providing actionable information that helps guide patients and physicians in making medical decisions during key life stages. The company applies a multi-omics approach, combining genomics, epigenomics, proteomics, and metabolomics to its molecular testing products and to the development of a suite of investigational ingestible devices designed to provide precise diagnostic sampling and drug delivery solutions. Progenity’s vision is to transform healthcare to become more precise and personal by improving diagnoses of disease and improving patient outcomes through localized treatment with targeted therapies.

Forward-Looking Statements

This press release contains “forward-looking statements,” which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. All statements, other than statements of historical facts included in this press release, including, but not limited to, Progenity’s expectations regarding the consummation of the offerings, the satisfaction of customary closing conditions with respect to the offerings and the anticipated use of the net proceeds are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “design,” “estimate,” “predict,” “potential,” “develop,” “plan” or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward looking statements. These statements involve known and unknown risks, uncertainties and other factors that could cause Progenity’s actual results to differ materially from the forward-looking statements expressed or implied in this press release, the uncertainties related to market conditions and the completion of the offerings on the anticipated terms or at all, the uncertainties inherent in the clinical drug development process, such as the regulatory approval process, the timing of regulatory filings, and other matters, including the ongoing COVID-19 pandemic and associated shelter-in-place orders, that could affect sufficiency of existing cash, cash equivalents and short-term investments to fund operations and the availability or commercial potential of Progenity’s products, and those risks described in “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Progenity’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, filed with the SEC on November 11, 2020, and other subsequent documents filed with the SEC. Progenity claim the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. Progenity expressly disclaims any obligation to update or alter any statements whether as a result of new information, future events or otherwise, except as required by law.

Contact Information

Investor Contact:
Robert Uhl
Managing Director, Westwicke ICR
[email protected]
(619) 228-5886

Media Contact:
Kate Blom-Lowery
CG Life
[email protected]
(858) 457-2436

SAN DIEGO, Dec. 02, 2020 (GLOBE NEWSWIRE) — Progenity, Inc. (“Progenity”) (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today announced the pricing of its previously announced underwritten public offering of 7,645,259 shares of its common stock at a public offering price of $3.27 per share. The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Progenity, are expected to be approximately $25.0 million. All of the shares are being offered by Progenity. Progenity has granted the underwriters a 30-day option to purchase up to an additional 1,146,788 shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on December 7, 2020, subject to the satisfaction of customary closing conditions. Progenity expects to use the net proceeds from the offering to support its operations, to invest in its molecular testing research and development program, to invest in research and development with respect to its precision medicine platform and for working capital and general corporate purposes.

In a separate press release, Progenity also announced today the pricing of its previously announced private offering of $75,000,000 aggregate principal amount of 7.25% convertible senior notes due 2025 (the “notes”), plus up to an additional $15,000,000 aggregate principal amount of notes that the initial purchaser of the notes has the option to purchase from Progenity. The issuance and sale of the notes are scheduled to settle on December 7, 2020, subject to customary closing conditions. The completion of the offering of common stock is not contingent on the completion of the offering of the notes, and the completion of the offering of notes is not contingent on the completion of offering of common stock. This press release does not constitute an offer to sell, or the solicitation of an offer to buy, any notes or any shares of common stock issuable upon conversion of the notes.

Piper Sandler & Co. and Wells Fargo Securities, LLC are acting as joint book-running managers for the offering of common stock. BTIG, LLC is acting as the lead manager for the offering of common stock.

A registration statement relating to the offering of common stock became effective on December 2, 2020. The offering is being made only by means of a prospectus, copies of which may be obtained from Piper Sandler & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, Minnesota 55402, or by telephone at (800) 747-3924, or by email at [email protected]; or Wells Fargo Securities, LLC, Attention: Equity Syndicate Department, 500 West 33rd Street, New York, New York, 10001, at (800) 326-5897 or email a request to [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About
Progenity

Progenity, Inc. is a biotechnology company with an established track record of success in developing and commercializing molecular testing products, as well as innovating in the field of precision medicine. Progenity provides in vitro molecular tests designed to improve lives by providing actionable information that helps guide patients and physicians in making medical decisions during key life stages. The company applies a multi-omics approach, combining genomics, epigenomics, proteomics, and metabolomics to its molecular testing products and to the development of a suite of investigational ingestible devices designed to provide precise diagnostic sampling and drug delivery solutions. Progenity’s vision is to transform healthcare to become more precise and personal by improving diagnoses of disease and improving patient outcomes through localized treatment with targeted therapies.

Forward Looking Statements

This press release contains “forward-looking statements,” which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. All statements, other than statements of historical facts included in this press release, including, but not limited to, Progenity’s expectations regarding the consummation of the offerings, the satisfaction of customary closing conditions with respect to the offerings and the anticipated use of the net proceeds are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “design,” “estimate,” “predict,” “potential,” “develop,” “plan” or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward looking statements. These statements involve known and unknown risks, uncertainties and other factors that could cause Progenity’s actual results to differ materially from the forward-looking statements expressed or implied in this press release, the uncertainties related to market conditions and the completion of the offerings on the anticipated terms or at all, the uncertainties inherent in the clinical drug development process, such as the regulatory approval process, the timing of regulatory filings, and other matters, including the ongoing COVID-19 pandemic and associated shelter-in-place orders, that could affect sufficiency of existing cash, cash equivalents and short-term investments to fund operations and the availability or commercial potential of Progenity’s products, and those risks described in “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Progenity’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, filed with the SEC on November 11, 2020, and other subsequent documents filed with the SEC. Progenity claim the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. Progenity expressly disclaims any obligation to update or alter any statements whether as a result of new information, future events or otherwise, except as required by law.

Investor Contact:
Robert Uhl
Managing Director, Westwicke ICR
[email protected]
(619) 228-5886

Media Contact:
Kate Blom-Lowery
CG Life
[email protected]
(619) 743-6294

REDWOOD CITY, Calif., Dec. 02, 2020 (GLOBE NEWSWIRE) — Codexis, Inc. (Nasdaq:CDXS), a leading protein engineering company, today announced the pricing of an underwritten public offering of 4,285,715 shares of its common stock at a public offering price of $17.50 per share. Net proceeds to Codexis from the offering are expected to be approximately $70.2 million after underwriting discounts and commissions and estimated offering expenses. The offering is expected to close on or about December 7, 2020, subject to customary closing conditions. Codexis has granted the underwriters of the offering the right for a period of 30 days to purchase up to an additional 642,857 shares of common stock at the public offering price, less underwriting discounts and commissions.

Jefferies LLC, Cowen and Company, LLC and Stifel, Nicolaus & Company, Incorporated are acting as joint book-running managers for the offering. Craig-Hallum Capital Group LLC and Stephens Inc. are acting as co-managers. The Benchmark Company acted as a financial advisor to Codexis in connection with the offering.

Codexis intends to use the net proceeds from the offering to fund research and development activities and infrastructure, to accelerate development of its performance enzyme products and novel biotherapeutic product candidates as well as any additional products or product candidates that Codexis may develop in the future, and for general corporate purposes, including increasing its working capital and capital expenditures. Codexis may also use a portion of the net proceeds to make investments in, or acquire, complementary businesses, products, services or technologies.

A registration statement relating to these securities has been filed with the U.S. Securities and Exchange Commission (SEC) and became effective on December 6, 2018. The offering is being made only by means of a written prospectus and prospectus supplement that will form a part of the registration statement. A preliminary prospectus supplement and the accompanying prospectus relating to the offering have been filed with the SEC and are available on the SEC’s website at www.sec.gov. A final prospectus supplement and accompanying prospectus will be filed with the SEC. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained, when available, by contacting Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by email at [email protected], or by telephone at (877) 821-7388; Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY 11717, Attention: Prospectus Department, or by telephone at (833) 297-2926, or by email at [email protected]; or Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, California 94104, or by telephone at 415-364-2720, or by email at [email protected].

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful, prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Codexis

Codexis is a leading protein engineering company that applies its proprietary CodeEvolver^® technology to develop proteins for a variety of applications, including as biocatalysts for the commercial manufacture of pharmaceuticals, fine chemicals and industrial enzymes, and enzymes as biotherapeutics and for use in molecular diagnostics. Codexis’ proven technology enables improvements in protein performance, meeting customer needs for rapid, cost-effective and sustainable manufacturing in multiple commercial-scale implementations of biocatalytic processes.

Forward-Looking Statements

To the extent that statements contained in this press release are not descriptions of historical facts regarding Codexis, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor of the Private Securities Litigation Reform Act of 1995, including Codexis’ expected use of the proceeds of the
public
offering. Such forward-looking statements involve substantial risks and uncertainties that could cause Codexis’ future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties related to market conditions and the completion of the public offering on the anticipated terms or at all. Codexis undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Codexis’ business in general, please refer to Codexis’ prospectus supplement to be filed with the SEC, including the documents incorporated by reference therein, which include
Codexis’
Annual Report on Form 10-K filed with the SEC on
February 28, 2020, Codexis’ Quarterly Report on Form 10-Q filed with the SEC on November 6, 2020
, and Codexis’ other periodic reports filed with the SEC.

Investor Relations Contact:
Argot Partners
Stephanie Marks/Natallia Clancy
(212)600-1902
[email protected]

VANCOUVER, British Columbia, Dec. 02, 2020 (GLOBE NEWSWIRE) — K92 Mining Inc. (“K92” or the “Company”) (TSX-V: KNT; OTCQX: KNTNF) is pleased to announce that it has been selected by the Prospectors & Developers Association of Canada (“PDAC”) to receive the 2021 Thayer Lindsley Award for the discovery of its Kora North deposit at its producing Kainantu Gold Mine in Eastern Highlands Province, Papua New Guinea.

The award recognizes an individual or team of explorationists credited with a recent significant mineral discovery globally and will be presented to the K92 Team during the annual PDAC Convention on March 9, 2021.

The award honours the memory of Thayer Lindsley, one of the most accomplished mine finders of the past century and who was inducted into the Canadian Mining Hall of Fame in 1989. Throughout Mr. Lindsley’s long and extraordinary career, he either founded or was involved in the development of many famous Canadian mining companies, including Falconbridge, Sherritt Gordon, Frobisher, Giant Yellowknife, Canadian Malartic and United Keno Hill.

Kora North Discovery Background

In 2015, K92 acquired the past producing Kainantu Gold Mine from Barrick Gold. The mine had been on care and maintenance for several years and had previously unprofitably mined the Irumafimpa deposit. When K92 restarted Kainantu, the focus was to mine the Irumafimpa deposit while exploring and developing other deposits. By questioning the geological model and acting on the reinterpretation, the K92 exploration team transformed the previously struggling mine into a highly profitable and rapidly expanding gold producer.

The breakthrough came in 2017, when K92 tested the thesis that two of the mine’s deposits, Kora and Eutompi, were in fact the same deposit. Previously, Eutompi was viewed as a distinct and lower grade deposit that was not of interest for step-out drilling, while K92 believed there was the potential for a higher grade, northern extension of Kora at depth, below Eutompi. As a result, the team modified the development design to access and drill this untested area from underground. The first drill hole intersected 5.4 metres grading 11.68 grams per tonne gold, 1.33% copper and 25.5 grams per tonne silver about 500 metres north of the Kora deposit and 400 metres below the Eutompi deposit. The discovery of Kora North had been made.

Since then, Kora’s measured, indicated and inferred resource has grown from 1.65 million ounces gold equivalent (“AuEq”) inferred to 1.1 million ounces AuEq measured and indicated and 3.7 million ounces AuEq inferred at a discovery cost of less than US$5 per ounce. The exceptional characteristics of the Kora North discovery have allowed Kainantu to operate at head grade of approximately 18 grams gold per tonne since commercial production, placing the mine among the highest-grade operations in the world. An operation that was struggling to achieve 30,000 ounces AuEq annual production is now on track to produce more than 300,000 ounces AuEq per year upon the completion of its Stage 3 Expansion which is expected to come online in late 2023. In addition, there are several high-priority targets close to current mining operations at Kainantu that promise to rapidly boost existing resources through both underground and surface drilling.

The Kora North discovery has transformed K92 and positioned Kainantu as one of the premier high-grade, long-life, low-cost underground precious metals mines in the world. The discovery has delivered significant value creation to K92 shareholders, and importantly, has also delivered tremendous economic benefits to the people of Papua New Guinea and the local communities. K92 employs over 95% PNG Nationals, of which a majority are from the local communities, is a meaningful contributor to the nation’s tax and royalty base, and is delivering significant business development and community programs.

John Lewins, K92 Chief Executive Officer and Director, stated, “We are extremely proud to receive this distinguished award, which we believe strongly recognizes the world-class nature of the Kainantu Gold Mine, the tremendous geologic potential of Papua New Guinea and the significant value creation from the K92 team. From drilling the Kora North discovery hole in May 2017, the rapid progress has been truly remarkable, achieving commercial production in late-January 2018, exceeding production guidance in both 2018 and 2019, and commissioning our Stage 2 Process Plant Expansion and completing the Stage 3 Expansion PEA in 3Q 2020. This would not have been possible if it weren’t for the extraordinary commitment of our team and the strong support of all levels of government in Papua New Guinea.

We
continue to
work at
expand
ing
the Kora deposit
as well as carrying out near mine exploration on multiple other targets including Judd and Karempe. The Company
currently
has
ten
diamond drill rigs
operating
on various targets
with
a
n eleventh
rig due in early 2021.
Significant high-grade results from n
ear mine exploration have recently
been
reported from underground drilling and underground development
at Judd as well as surface drilling at Karempe
. With only 20% of the near mine vein field drill tested
,
there
remains
very significant potential for further expan
sion of
resources
in and around the K
ai
nantu Mine
and we continue to add more drill rigs
as results warrant
.”

Jerry Garry, Managing Director, Mineral Resources Authority of Papua New Guinea (“MRA”), stated “As the Managing Director of the MRA and a geologist, I am pleased and proud for a notable world-class discovery in Papua New Guinea to be the recipient of the prestigious Thayer Lindsley award for the first time. The MRA strongly supported the restart of the Kainantu Mine by K92 Mining and we have followed closely the transformation of Kainantu from the initial discovery of Kora North to a robust and growing mine. I strongly believe that the future is very bright not only for the Kainantu Mine but also the Resource Industry in PNG.”

Global Kora
Mineral Resource
(Effective Date April 2, 2020)

	Tonnes	Gold		Silver		Copper		AuEq
	mt	g/t	moz	g/t	moz	%	kt	g/t	moz
Measured	0.66	13.34	0.28	11.6	0.25	0.51	3.4	14.14	0.3
Indicated	2.47	8.44	0.67	16.3	1.29	0.63	15.6	9.46	0.8
Total M&I	3.13	9.47	0.95	15.3	1.54	0.61	19	10.45	1.1
Inferred	12.67	7.32	2.98	19.9	8.11	1.1	139.4	9.01	3.7

• Mineral Resource Estimate is included in a technical report titled,
  “
  Revised
  Independent Technical Report, Mineral Resource Estimate Update and Preliminary Economic Assessment for Expansion of the Kainantu Mine to Treat 1 Mtpa from the Kora Gold Deposit, Kainantu Project, Papua New Guinea”
  with an effective date of April 2, 2020.
• The Independent and Qualified Person responsible for the Mineral Resource Estimate is Simon Tear,
  P.Geo
  . of H & S Consultants Pty. Ltd., Sydney, Australia.
• Mineral Resources are not Mineral Reserves and do not have demonstrated economic viability.
• Resources were compiled at 1,2,3,4,5,6,7,8,9 and 10 g/t gold cut-off grades.
• Density (t/m
  
  ³
  
  ) is on a per zone basis,
  K1
  and
  Kora Link: 2.84 t/m
  
  ³
  
  ; K2: 2.93 t/m
  
  ³
  
  ; Waste: 2.8 t/m
  
  ³
  
• Reported tonnage and grade figures are rounded from raw estimates to reflect the order of accuracy of the estimate.
• Minor variations may occur during the addition of rounded numbers.
• Calculations used metric units (metres,
  tonnes
  and g/t)
  .
• Gold equivalents are calculated as AuEq = Au g/t + ((0.923 x Cu
  %)*
  1.38)+ (0.77 x Ag g/t*0.0115)). Gold price US$1,400/oz; Silver US$16.05/oz; Copper US$3.05/lb. Metal payabilities and recoveries are incorporated into the AuEq formula. Recoveries of 92.3% for copper and 77% for silver.
  

Qualified Person
s

K92 Vice President Exploration, Mr. Chris Muller, PGeo, a Qualified Person under the meaning of National Instrument 43-101 – Standards of Disclosure for Mineral Projects, has reviewed and is responsible for the technical content of this news release.

K92 Mine Geology Manager and Mine Exploration Manager, Andrew Kohler, PGeo, a Qualified Person under the meaning of Canadian National Instrument 43-101 – Standards of Disclosure for Mineral Projects, has reviewed and is responsible for the technical content of this news release.

About K92

K92 Mining Inc. is engaged in the production of gold, copper and silver from the Kora deposit at the Kainantu Gold Mine in the Eastern Highlands province of Papua New Guinea, as well as exploration and development of mineral deposits in the immediate vicinity of the mine. The Company declared commercial production from Kainantu in February 2018 and is in a strong financial position. K92 is operated by a team of mining company professionals with extensive international mine-building and operational experience.

On Behalf of the Company,

John Lewins, Chief Executive Officer and Director

For further information, please contact
David Medilek, P.Eng., CFA
at +1-604-687-7130.

NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION: This news release includes certain “forward-looking statements” under applicable Canadian securities legislation. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. All statements that address future plans, activities,
events,
or developments that the Company believes, expects or anticipates will or may occur are forward-looking information, including statements regarding the realization of the preliminary economic analysis for the
Kainantu Project
, expectations of future cash flows, the
planned
plant expansion,
production results, cost of sales, sales of production,
potential expansion of resources
and the generation of further drilling results which may or may not occur. Forward-looking statements and information contained herein are based on certain factors and assumptions regarding, among other things, the market price of the Company’s securities, metal prices, exchange rates, taxation, the estimation, timing and amount of future exploration and development, capital and operating costs, the availability of financing, the receipt of regulatory approvals, environmental risks, title disputes, failure of plant, equipment or processes to operate as anticipated, accidents, labour disputes, claims and limitations on insurance coverage and other risks of the mining industry, changes in national and local government regulation of mining operations
in PNG
,
mitigation of the Covid-19 pandemic, continuation of the lifted state of emergency,
and regulations and other matters. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

NEW ORLEANS, Dec. 02, 2020 (GLOBE NEWSWIRE) — Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits:

Turquoise Hill Resources Ltd. (TRQ


)


Class Period: 7/17/2018 – 7/31/2019
Lead Plaintiff Motion Deadline: December 14, 2020
SECURITIES FRAUD
To learn more, visit https://www.ksfcounsel.com/cases/nyse-trq/

First American Financial Corp. (FAF)


Class Period: 2/17/2017 – 10/22/2020
Lead Plaintiff Motion Deadline: December 24, 2020
SECURITIES FRAUD
To learn more, visit https://www.ksfcounsel.com/cases/nyse-faf/

Raytheon Technologies Corporation f/k/a Raytheon Company (RTX, RTN)


Class Period: 2/10/2016-10/27/2020
Lead Plaintiff Motion Deadline: December 29, 2020
SECURITIES FRAUD
To learn more, visit https://www.ksfcounsel.com/cases/nyse-rtx/

If you purchased shares of the above companies and would like to discuss your legal rights and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner, Lewis Kahn, toll-free at 1-877-515-1850, via email ([email protected]), or via the case links above.

If you wish to serve as a Lead Plaintiff in the class action, you must petition the Court on or before the Lead Plaintiff Motion deadline.

About
KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. KSF serves a variety of clients – including public institutional investors, hedge funds, money managers and retail investors – in seeking to recover investment losses due to corporate fraud and malfeasance by publicly traded companies. KSF has offices in New York, California and Louisiana.

To learn more about KSF, you may visit www.ksfcounsel.com.

Contact:

Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
[email protected]
1-877-515-1850
1100 Poydras St., Suite 3200
New Orleans, LA 70163

NEW ORLEANS, Dec. 02, 2020 (GLOBE NEWSWIRE) — Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigation into Citigroup Inc. (NYSE: C).

On August 12, 2020, it was revealed that the Company had inadvertently wired $900 million of its own money to various lenders of Revlon Inc., seemingly intended as an interest payment from Revlon on a loan for which Citibank acts as an administrative agent, which it later referred to as “an operational mistake.” Then, on October 7, 2020, U.S. banking regulators announced a $400 million fine and other consent orders entered against the Company for “longstanding” risk management, data governance and internal controls deficiencies. Then, on October 13, 2020, the Company reported a 5% increase in expenses during the third quarter, to a total of $11 billion, due in part to additional costs related to regulatory fines, investments in infrastructure, and other remediation costs related to control deficiencies.

KSF’s investigation is focusing on whether Citigroup’s officers and/or directors breached their fiduciary duties to Citigroup’s shareholders or otherwise violated state or federal laws.

If you have information that would assist KSF in its investigation, or have been a long-term holder of Citigroup shares and would like to discuss your legal rights, you may, without obligation or cost to you, call toll-free at 1-877-515-1850 or email KSF Managing Partner Lewis Kahn ([email protected]), or visit https://www.ksfcounsel.com/cases/nyse-c/ to learn more.

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. KSF serves a variety of clients – including public institutional investors, hedge funds, money managers and retail investors – in seeking to recover investment losses due to corporate fraud and malfeasance by publicly traded companies. KSF has offices in New York, California and Louisiana.

To learn more about KSF, you may visit www.ksfcounsel.com.

Contact:

Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
[email protected]
1-877-515-1850
1100 Poydras St., Suite 3200
New Orleans, LA 70163